麻桔喘咳口服液临床前基础研究

Preclinical basic research of Majuchuanke oral liquid

目的:根据麻桔喘咳口服液的功能与主治,对其进行安全性评价和主要药效学研究,为其进一步研究开发提供依据。方法:急性毒性试验:测定其半数致死量(LD50)。主要药效学试验:采用小鼠氨水引咳法观察其止咳作用;采用酚红祛痰法观察其祛痰作用;采用大鼠肉芽肿试验观察其抗炎作用;采用小鼠耐缺氧试验(钠石灰法)观察其抗应激的能力。结果:麻桔喘咳口服液的LD50为97.64g生药/kg。主要药效学试验中,除小鼠耐缺氧实验外,止咳、祛痰、抗炎三个实验结果显示,给药组与对照组比较,差异有显著性(P<0.05)。结论:麻桔喘咳口服液的LD50为97.64g生药/kg;主要药效学试验结果表明其具有止咳、祛痰、抗炎等作用,为其进一步研发奠定了基础。

Objective: To evaluate the safety and study the pharmacodynamics of Majuchuanke oral liquid, according to its functions and indications. Method: The median lethal dose (LD50) was investigated in acute toxicity test. The effect of stopping cough of Majuchuanke oral liquid was observed by mice ammonia induced cough test. The effect of eliminating phlegm of Majuchuanke oral liquid was observed by mice phenol red secretion test. The anti-inflammatory effect was observed by rat granuloma test. The anti-stress effect was observed by mice hypoxia tolerance test. Result: The LD50 of Majuchuanke oral liquid was 97.64g crude drug·kg-1. Comparing the results of administration group and the control group, Majuchuanke oral liquid was better than the control group in the antitussive, expectorant and anti-inflammatory aspects except the hypoxia tolerance capability. Conclusion: The LD50 of Majuchuanke oral liquid is 97.64g crude drug·kg-1.The results of main pharmacodynamic test show that majuchuanke oral liquid has antitussive, expectorant and anti-inflammatory effect, laying the foundation for the further development of Majuchuanke oral liquid.